STX-200

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameSTX-200
Drug Alias Namealpha-v/beta-5 mAb (Stromedix)alpha-v/beta-5 monoclonal antibody (University of California San Francisco)alpha-v/beta-5 monoclonal antibody (Stromedix)alpha-v/beta-5 antagonist (Stromedix)alpha-v/beta-5 mAb (University of California San Francisco) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIntegrin alpha-V/beta-5 antagonists
TargetsIntegrin alpha-V/beta-5
Therapy Area/IndicationsMultiple Organ FailureFibrosisScleroderma, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStromedix Inc
Active IndicationsN/A
Inactive IndicationsMultiple Organ FailureFibrosisScleroderma, Systemic +[5] 

Other Information

ATC CodeN/A
Related LinksN/A